Publication Name	World Journal of Transplantation
Manuscript ID	21071
Country	Italy

Received	2015-06-29 18:48
Peer-Review Started	2015-07-05 20:17
First Decision by Editorial Office Director
Return for Revision	2015-09-19 10:26
Revised	2016-03-22 00:00
Publication Fee Transferred
Second Decision by Editor	2016-04-01 08:31
Second Decision by Editor-in-Chief	2016-04-03 19:44
Final Decision by Editorial Office Director	2016-04-11 11:22
Articles in Press	2016-04-11 17:18
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-05-17 16:45
Publish the Manuscript Online	2016-06-22 16:18

ISSN	2220-3230 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Minireviews
Article Title	First line vs delayed transplantation in myeloma: Certainties and controversies
Manuscript Source	Invited Manuscript
All Author List	Annamaria Brioli
Funding Agency and Grant Number
Corresponding Author	Annamaria Brioli, MD, PhD, Klinik für Innere Medizin Ⅱ (Abteilung Hämatologie und internistische Onkologie), Universitätsklinikum Jena, Erlanger Allee 101, 07740 Jena, Germany. annamaria.brioli2@unibo.it
Key Words	Autologous stem cell transplantation; Immunomodulatory drugs; Proteasome inhibitors; High dose therapy; Multiple myeloma
Core Tip	Autologous stem cell transplantation (ASCT) is the cornerstone for the treatment of young multiple myeloma patients. This review summarizes the current knowledge on ASCT, with a special focus on the role of ASCT in the era of novel agents for multiple myeloma treatment.
Publish Date	2016-06-22 16:18
Citation	Brioli A. First line vs delayed transplantation in myeloma: Certainties and controversies. World J Transplant 2016; 6(2): 321-330
URL	http://www.wjgnet.com/2220-3230/full/v6/i2/321.htm
DOI	http://dx.doi.org/10.5500/wjt.v6.i2.321

Full Article (PDF)	WJT-6-321.pdf
Full Article (Word)	WJT-6-321.doc
Manuscript File	21071-Review.docx
Answering Reviewers	21071-Answering reviewers.pdf
Audio Core Tip	21071-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	21071-Conflict-of-interest statement.pdf
Copyright License Agreement	21071-Copyright assignment.pdf
Peer-review Report	21071-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	21071-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	21071-Scientific misconduct check.pdf
Scientific Editor Work List	21071-Scientific editor work list.pdf